13th Annual World Bispecific Summit

The 13th World Bispecific Summit is the Only End-to-End Meeting Committed Solely to Advancing the Development of Bi- and Multi-Specific Therapeutics

With more clinical candidates and commercial success than ever within this rapidly developing space, multi-specifics is evidently the fourth wave of drug discovery. With this, there has never been a hotter time to double down and deliver the holy grail of precision oncology as the true power of bispecifics is recognized.

The 13th World Bispecific Summit will deliver a greater scope and penetration of innovative technical content than any other meeting. This year's re-imagined agenda will cover unique target discovery, mechanistic diversity and translational science as well as novel formats, product design and manufacturability challenges faced in the bispecific field.

Whatever your role or interest, you will leave the meeting with concrete methods to employ in your strategy and pipeline to convert the promise of bi- and multi-specific therapeutics into a reality for patients.

With 2 tracks of unrivaled content, join with your team to catapult this community into the next generation of translational success, clinical progress, advanced mechanistic diversity, reduced toxicity and higher target affinity. Utilize the pre-conference focus day dedicated to Novel Formats and Immune Cell Modulators of multispecifics to further drive your clinical and antibody engineering strategies forward.

URLs:
Website: https://go.evvnt.com/1160671-0?pid=176 
Tickets: https://go.evvnt.com/1160671-2?pid=176 
Brochure: https://go.evvnt.com/1160671-3?pid=176 

Prices:
Conference + Focus Day - Industry Pricing: USD 4646.00,
Conference Only - Industry Pricing: USD 2999.00,
Conference + Focus Day - Academic and Non-Profit Pricing: USD 3946.00,
Conference Only - Academic and Non-Profit Pricing: USD 2599.00,
Conference + Focus Day - Service Provider Pricing: USD 5546.00,
Conference Only - Service Provider Pricing: USD 3599.00

Speakers: Alex Martinko, Co-Founder and Senior Director - Protein Science, Soteria Biotherapeutics, Alexander Haas, Head Biologics Core Technologies, Roche, Aman Singh, Associate Director, Cell Therapy Clinical Pharmacology, Modeling and Bioinformatics, Takeda, Ankita Srivastava, Vice President - Protein Sciences and Rational Design, Ichnos Sciences, Anthony Stein, Medical Doctor, City of Hope, Azra Mujic-Delic, Principal Scientist - Functional Characterization and Bioassays, Genmab, Brandon Leonard, Principal Scientific Researcher - Antibody Engineering, Genentech, Camille Grandclement, Senior Scientist, Ichnos Sciences, Chava Kimchi-Sarfat,y Deputy Associate Director - Research Office of Tissue and Advanced Therapies, CBER, FDA, Christopher Mehlin, Chief Scientific Officer and Co-founder, Link Immunotherapeutics, Daniel Pereira, Chief Scientific Officer, Invenra, David Poon, Vice President - Business Development and Alliance Management, Zymeworks, Diego Ellerman, Principal Scientific Researcher, Genentech, Erin Meermeier, Research Associate Scientist - Division of Hematology and Oncology, Mayo Clinic, Eugene Zhukovsky, Chief Scientific Officer, Ichnos Sciences, Ezio Bonvini, Chief Scientific Officer, Macrogenics, Harald Kolmar, Department Head Applied Biochemistry Technical, University of Darmstadt, Jeffrey Way, Lecturer - Department of Systems Biology, Harvard Medical School, Jonah Rainey, Vice President of Antibody Engineering and Protein Science, AlivaMab Discovery Services, Jonathan Davis, Vice President - Innovation and Strategy, Invenra, Julia Frei, Principal Scientist, Ichnos Sciences, Kalyan Pande, Associate Principal Scientist - Protein Engineering and Modalities, Merck, Liqin Liu Senior, Director of T Cell Engagers, IGM Biosciences, Martin Siegemund, Senior Scientist, Pieris Pharmaceuticals, Nimish Gera, Vice President - Biologics Research, Mythic Therapeutics, Peter Ellmark, Chief Scientific Officer, Alligator Bioscience, Pranjali Dalvi, Senior Scientist, Amgen, Prathap Shastri, Scientific Director, DMPK, Preclinical Sciences and Translational Safety, Johnson and Johnson, Rakesh Dixit, President and Head of R and D, Co-Founder, Regio Biosciences, Alexander Schinagl, PhD Chief Technology Officer, OncoOne, Shailee Patel, Researcher Beacon, Targeted Therapeutics, Shaun Lippow, Senior Director - Protein Engineering, Atreca, Suzanne Schubbert, Associate Director - Discovery Biology and Pharmacology, Xencor, Vera Sellers, Associate Director - Molecule Group, Protein and Cell Sciences Discovery and Development Technologies, EMD Serono, Wadim Matochko, Scientist Antibody Discovery, Amgen, Wei Yan, President and Chief Executive Officer, Sound Biologics, Werner Meier, Chief Scientific Officer, Revitope Oncology, Yanchen Zhou, Scientist, Amgen, Musheng Bao, Senior Director, Discovery Oncology, Harbour Biomed, Christel Iffland, PhD. VP, Antibody Technology, OmniAb, Inc.

Time: 08:30 - 17:00